Chasing the Miracles of Science to Improve Lives

The Power of Chasing A Dream

Every day, we chase the miracles of science to improve people’s lives. We apply our deep understanding of the immune system to develop breakthrough innovations in medicines and vaccines so you can focus on what matters most, chasing your dreams. So, if you’re chasing your dreams, remember... you’re not alone. We’re right beside you.

People Stories

People are at the heart of every breakthrough. Across the world, individuals from the lab to the community are redefining what’s possible, whether they’re living with complex conditions, advancing pioneering research or helping deliver care that can transform lives. These stories celebrate the people who continue to chase their dreams despite living with a disease, and Sanofians who chase the miracles of science to make those dreams possible.

We’re inspired by the strength, courage, and hope of these people who remind us why our purpose matters - we chase the miracles of science to improve people’s lives. For some, that means finding new ways to manage chronic diseases. For others, it’s about breaking boundaries in science to bring life-changing solutions to patients faster. Together, their journeys reflect our shared belief that improved health unlocks the potential to make dreams a reality.

Céline, from Diagnosis to World Champion Para-surfer

Diagnosed with secondary progressive multiple sclerosis (SPMS) at 30, Céline — who previously described herself as not "sporty at all" — radically reimagined her life. Despite rapidly progressing symptoms affecting her mobility, she chose to pursue what she loves. Through art, para-surfing, and a deep belief in medical science, Céline transformed despair into a dynamic new chapter. Today, she's not only a thriving artist but also captain of the French para-surfing team and a two-time World Champion. Her incredible journey is a powerful testament to resilience, innovation, and the spirit's ability to turn dreams into reality, one wave at a time.

Xavier, a Filmmaker Advocating for Diabetes Representation

At 18, a life-altering autoimmune type 1 diabetes diagnosis ended Xavier's football aspirations but opened an unexpected new path. He traded the field for the stage, discovering a passion for the arts. Today, he's a celebrated filmmaker, writer, and advocate, aiming to create powerful, meaningful diabetes representation on screen. Empowered by visible role models and driven by fatherhood, Xavier champions awareness and embraces scientific advancements that make his dreams possible, proving that a diagnosis can ignite a new, inspiring chase.

Jade, Thriving Despite Atopic Dermatitis

Adopted from Vietnam and diagnosed with atopic dermatitis at three months old, Jade has faced a lifetime of challenges, from intense itching to disrupted sleep. Yet, she refuses to let her condition define her. Instead, she embraces adventure, completing demanding rallies like the 4L Trophy, an annual humanitarian and sporting rally for students, through the Moroccan desert, and channels her experiences into creative expression through music and children's books, including "Lorni et l'eczéma". Jade's journey is a powerful testament to resilience, showing how medical progress, combined with an unwavering spirit, can transform chronic conditions into a source of empowerment and inspiration for herself and others.

Kathi, National Champion and Type 1 Diabetes Advocate

Diagnosed with autoimmune type 1 diabetes (T1D) at 21, Kathi Korn faced a period of deep despair, believing her dreams of motherhood and an athletic career were over. But pregnancy became her turning point, fueling a fierce determination to reclaim her life. She started a YouTube channel to share vital information about T1D and pregnancy, quickly building a thriving community. Kathi not only became a national table tennis champion and a Miss Germany finalist, but also a powerful advocate, authoring a children's book and becoming an ambassador for T1D awareness. Her journey, powered by scientific advancements and an unyielding spirit, shows how a diagnosis can ignite a mission to empower countless others living with T1D.

Nadine, from Black Belt Resilience to Breakthrough Science

Nadine, Sanofi's Cluster Head of Immunology Research, channels her black belt-forged resilience into the challenging world of drug development. Her martial arts background instilled the perseverance and adaptability that are vital in a field where breakthroughs are rare. Driven by a deep desire to understand patients and profoundly impact their lives, her ultimate dream is to see a drug she's worked on gain approval, transforming the lives of those battling autoimmune diseases.

Géraldine's Journey: Finding Purpose in Every Breath

Diagnosed with chronic obstructive pulmonary disease (COPD) in 2014, former emergency department nurse Géraldine faced a devastating challenge that mirrored her father's struggle. The disease, which made even simple movements difficult, threatened to steal her active life. However, a life-threatening hospitalization in 2019 became her turning point. From that moment, Géraldine committed to helping others with COPD. Now an "expert patient" and mentor, she shares her experiences in rehabilitation centers, advocating for activity, community, and the vital role of medical innovation. Her story is a powerful testament to transforming personal struggle into a mission to uplift others, showing how resilience and science can enable dreams even amidst adversity.

Wei, Fueling Drug Discovery with AI and Resilience

Wei Jiang, a Principal Scientist in artificial intelligence at Sanofi, is at the forefront of revolutionizing drug discovery. Driven by a deep commitment to excellence and a pragmatic approach, she was instrumental in creating one of Sanofi's first fully automated labs, capable of executing thousands of experiments daily with robotic precision. Her ambition is fueled by a personal connection—her grandmother lives with COPD—and a belief that physical strength cultivates mental resilience. Wei's ultimate dream is to see her research proposals advance into clinical trials, accelerating the delivery of life-changing therapies to patients worldwide. She embodies the powerful combination of scientific innovation and unwavering determination.

“Having a dream since my diagnosis truly changed my vision of things. Anything is possible.”

Céline, 2x World Champion para-surfer

We Chase the Miracles of Science to Improve People’s Lives

Innovation begins with curiosity, and at Sanofi, that curiosity drives us to chase the miracles of science every day. Across our global research network, thousands of scientists, engineers, and partners are breaking boundaries in science to bring life-changing solutions to patients faster. Guided by one purpose-we chase the miracles of science to improve people’s lives-we are transforming the future of medicine through discovery, technology, and collaboration.

From dermatological and respiratory conditions like atopic dermatitis and chronic obstructive pulmonary disease (COPD) to autoimmune and neurological diseases such as multiple sclerosis and autoimmune type 1 diabetes, we’re chasing the miracles of science to address the root causes of diseases, not just the symptoms, to create lasting change. These breakthroughs exemplify our commitment to deliver high-quality, affordable, sustainable medicines and vaccines to those who need them most, ensuring innovation translates into real-world impact. We chase the miracles of science for a healthier, more resilient world, harnessing cutting-edge science, technology, and human insight to shape a better future for generations to come.

Every discovery at Sanofi is a step toward a healthier, more hopeful future. Health unlocks the potential to make dreams a reality, and through innovation, we’re helping people around the world do just that

Revolutionizing Autoimmune Type 1 Diabetes Care

Type 1 diabetes (T1D) is an autoimmune, progressive and lifelong condition that can develop at any age.¹ Whilst anyone can develop type 1 diabetes, if just one first-degree relative has T1D, the risk of diagnosis increases by up to 15x.² However, around 90% of those who develop type 1 diabetes do not have a family history of the condition.³ T1D affects approximately 9.2 million people globally, and demands consistent, daily management.^4,5 Scientific breakthroughs have revealed that T1D is an autoimmune disease where the body’s immune system mistakenly attacks insulin-producing cells.⁶ This discovery opens the door to new approaches for research. At Sanofi, we’re chasing the miracles of science to transform the lives of people living with autoimmune T1D, both in the UK and around the world.

Transforming COPD Treatment

Chronic Obstructive Pulmonary Disease (COPD)  is a progressive and potentially life-threatening respiratory illness, and currently the fourth leading cause of death globally, with great physical and emotional impacts.^7-8 For decades, treatment focused on managing symptoms (like shortness of breath), lifestyle advice (smoking cessation and moderate exercise), and pulmonary rehabilitation. However, our latest immunoscience research has unveiled a new insight: COPD is driven by persistent inflammation within the lungs, stemming from the immune system.¹⁰ We've discovered that inflammatory pathways, like those in autoimmune diseases, contribute significantly to lung damage, even after environmental triggers are gone. By understanding these complex immune mechanisms, we're targeting underlying inflammatory drivers. Our goal is to transform treatment, enabling people with COPD to breathe easier, live fuller lives, and regain the freedom to chase their dreams.

A Future Unbound by Atopic Dermatitis

Atopic dermatitis is more than just a skin condition; it's a chronic inflammatory disease stemming from an overactive immune response deep within the body.¹¹ While some standard treatments focus on surface symptoms¹², our science has shifted to target the underlying immunological pathway. We're exploring innovative ways to interrupt the inflammatory cascade at an earlier stage blocking the immune system's overreactions before they can lead to severe pain, redness, and flare-ups. By focusing on early interventions, our goal is to revolutionise atopic dermatitis treatment.¹³ We aim to help patients have a life with improved symptoms, empowering them to move beyond the limitations of their condition and not allowing atopic dermatitis to dictate their lives.¹³

Reshaping the Future of Multiple Sclerosis

Multiple Sclerosis (MS) is a complex, unpredictable disease where many patients experience disability progression even without relapses.¹⁴ For a long time, the underlying cause of this progression was unclear. Our research has unveiled a critical insight: MS is significantly driven by neuroinflammation. Immune cells mistakenly cross the blood-brain barrier, attacking healthy neurons and activating protective brain cells (microglia) against themselves.¹⁵ This leads to a chronic, low-level blaze of inflammation that causes slow but progressive damage.¹⁶By understanding this connection between the immune system and nerve cells, we're blazing a transformative scientific path. Our goal is to leverage our deep knowledge of immune processes to target and halt neuroinflammation, slow disease progression, and ultimately improve the quality of life for people living with MS, helping them live for the moment, not the disease.

MAT-XU-2505043 v1.0

Date of Preparation: June 2026

References

Insel RA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 2015;38(10):1964-1974.
Parkkola A, Harkonen T, Ryhanen SJ, llonen J,.et al; Finnish Pediatric Diabetes Register. Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children. Diabetes Care. 2013 Feb;36(2):348-54.
Sims EK, et al. Screening for type 1 diabetes in the general population: A Status Report and Perspective. Diabetes. 2022;71(4):610-623.
International Diabetes Federation. Type 1 Diabetes. Available at https://idf.org/about- diabetes/types-of-diabetes/type-1-diabetes/. Last accessed: April 2026.
PhD, Aaron Breedlove. “The Mental Health Effects of Type 1 Diabetes.” Osu.edu, The Ohio State University, 13 June 2025, health.osu.edu/health/mental-health/managing- diabetes-and-mental-health.
Diabetes. Beta Cells. Available at: https://www.diabetes.co.uk/body/beta-cells.html. Last accessed: April 2026.
World Health Organisation. “Chronic obstructive pulmonary disease (COPD)” Available at: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Last accessed : April 2026
Mathioudakis, Alexander G., Sachin Ananth, and Jørgen Vestbo. "Stigma: an unmet public health priority in COPD." The Lancet Respiratory Medicine 9.9 (2021): 955-956.
NHS. ‘Chronic Obstructive Pulmonary Disease (COPD) – Treatment’. Available at: https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/treatment/ Last accessed: April 2026
Oh JY, Sin DD. Lung inflammation in COPD: why does it matter? F1000Research. 2012;4:23.
Cork MJ, Danby SG, Ogg GS. “Atopic dermatitis epidemiology and unmet need in the United Kingdom“ PubMed, The Journal of Dermatological Treatment. 2020;8:801-809.
Lusignan SD, et al. “Patterns and trends in eczema management in UK primary care (2009-2018): A population-based co-hort study”, PubMed, Clin Exp Allergy, 2021:51(3):483-494
Sanofi UK & Ireland. “Skin in the Game: Raising atopic eczema (atopic dermatitis) awareness”. Available at: https://www.sanofi.co.uk/en/your-health/medicines/skin-in-the-game Last accessed: April 2026
Frisch ES, Pretzsch R, Weber MS. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues. Neurotherapeutics. 2021;18:1602-1622. 
Mandolesi G, Gentile A, Musella A, Fresegna D, De Vito F, Bullitta S, Sepman H, Marfia GA, Centonze D. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nature Review Neurology. 2015;11:711-724
Häusser-Kinzel S, Weber MS. The role of B cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders. Front Immunol. 2019;10:201.